China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 71,896 shares, an increase of 1,295.8% from the May 31st total of 5,151 shares. Currently, 0.2% of the company’s stock are short sold. Based on an average daily trading volume, of 220,625 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of China SXT Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new stake in China SXT Pharmaceuticals in the third quarter valued at $78,000. XTX Topco Ltd acquired a new position in China SXT Pharmaceuticals during the 4th quarter worth $36,000. Finally, Virtu Financial LLC grew its holdings in China SXT Pharmaceuticals by 107.5% during the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after acquiring an additional 15,013 shares in the last quarter. 5.02% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

China SXT Pharmaceuticals Stock Performance

Shares of SXTC traded down $0.19 during trading on Thursday, reaching $2.35. The company’s stock had a trading volume of 15,429 shares, compared to its average volume of 191,885. The company has a fifty day moving average of $1.89 and a two-hundred day moving average of $41.98. China SXT Pharmaceuticals has a twelve month low of $1.25 and a twelve month high of $1,046.98.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.